<SEC-DOCUMENT>0001104659-20-043704.txt : 20200406
<SEC-HEADER>0001104659-20-043704.hdr.sgml : 20200406
<ACCEPTANCE-DATETIME>20200406162331
ACCESSION NUMBER:		0001104659-20-043704
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20200331
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200406
DATE AS OF CHANGE:		20200406

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Replimune Group, Inc.
		CENTRAL INDEX KEY:			0001737953
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				822082553
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38596
		FILM NUMBER:		20777249

	BUSINESS ADDRESS:	
		STREET 1:		500 UNICORN PARK
		CITY:			WOBURN
		STATE:			MA
		ZIP:			01801
		BUSINESS PHONE:		(781) 222-9600

	MAIL ADDRESS:	
		STREET 1:		500 UNICORN PARK
		CITY:			WOBURN
		STATE:			MA
		ZIP:			01801
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2015110d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM&nbsp;8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section&nbsp;13 or 15(d)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
<B>March 31, 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPLIMUNE GROUP, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 34%; text-underline-color: #000000; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; text-underline-color: #000000">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 32%; text-underline-color: #000000; text-align: center"><FONT STYLE="font-size: 10pt"><B>001-38596</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; text-underline-color: #000000">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 32%; text-underline-color: #000000; text-align: center"><FONT STYLE="font-size: 10pt"><B>82-2082553</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-underline-color: #000000; text-align: center"><FONT STYLE="font-size: 10pt">(State or other jurisdiction<BR>
of incorporation)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-underline-color: #000000">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-underline-color: #000000; text-align: center"><FONT STYLE="font-size: 10pt">(Commission<BR>
File Number)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-underline-color: #000000">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-underline-color: #000000; text-align: center"><FONT STYLE="font-size: 10pt">(IRS Employer<BR>
Identification Number)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>500 Unicorn Park</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Woburn, MA 01801 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices,
including Zip Code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&#8217;s telephone number, including
area code: <B>(781) 222-9600</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form&nbsp;8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Wingdings">o</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Wingdings">o</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Wingdings">o</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Pre-commencement communications pursuant to Rule&nbsp;14d-2(b)&nbsp;under the Exchange Act (17 CFR 240.14d-2(b))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Wingdings">o</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Pre-commencement communications pursuant to Rule&nbsp;13e-4(c)&nbsp;under the Exchange Act (17 CFR 240.13e-4(c))&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; width: 33%; text-underline-color: #000000; text-align: center"><FONT STYLE="font-size: 10pt">Title of each class</FONT></TD>
    <TD STYLE="width: 2%; text-underline-color: #000000; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 11%; text-underline-color: #000000; text-align: center"><FONT STYLE="font-size: 10pt">Trading<BR>
 Symbol(s)</FONT></TD>
    <TD STYLE="width: 2%; text-underline-color: #000000; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 52%; text-underline-color: #000000; text-align: center"><FONT STYLE="font-size: 10pt">Name of each exchange on which registered</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: #000000; text-align: center"><FONT STYLE="font-size: 10pt">Common Stock, par value $0.001 per share</FONT></TD>
    <TD STYLE="text-underline-color: #000000; text-align: center">&nbsp;</TD>
    <TD STYLE="text-underline-color: #000000; text-align: center"><FONT STYLE="font-size: 10pt">REPL</FONT></TD>
    <TD STYLE="text-underline-color: #000000; text-align: center">&nbsp;</TD>
    <TD STYLE="text-underline-color: #000000; text-align: center"><FONT STYLE="font-size: 10pt">The Nasdaq Stock Market LLC (Nasdaq Global Select Market)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule&nbsp;405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule&nbsp;12b-2 of
the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).&nbsp;&nbsp;Emerging growth company <FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section&nbsp;13(a)&nbsp;of the Exchange Act.&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Wingdings; margin: 0pt 0"></P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 10%; text-underline-color: #000000"><FONT STYLE="font-size: 10pt"><B>Item 5.02</B></FONT></TD>
    <TD STYLE="text-align: justify; width: 90%; text-underline-color: #000000"><FONT STYLE="font-size: 10pt"><B>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Appointment of Paulo Pucci to the Board of Directors</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Effective as of April
1, 2020 (the &#8220;<U>Effective Date</U>&#8221;), based on the recommendation of the Nominating and Corporate Governance Committee
of Replimune Group,&nbsp;Inc. (the &#8220;<U>Company</U>&#8221;), the Board of Directors of the Company (the &#8220;<U>Board</U>&#8221;)
increased the size of the Board from nine members to ten and filled the newly created vacancy on the Board by appointing Paolo
Pucci&nbsp;as a director&nbsp;of the Company. Mr.&nbsp;Pucci&nbsp;will initially serve as a&nbsp;director of the Company until
the Company&#8217;s 2020 annual meeting of stockholders, at which such meeting Mr. Pucci will be nominated to stand for election
to the Board. The Board has determined that Mr.&nbsp;Pucci&nbsp;is an independent director in accordance with applicable rules&nbsp;of
the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) and the Nasdaq Stock Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr.&nbsp;Pucci&nbsp;most
recently served as the Chief Executive Officer of ArQule, Inc., a biopharmaceutical oncology company engaged in the research and
development of targeted therapeutics that was acquired by Merck in&nbsp;January 2020. Prior to joining ArQule, Inc. in 2008,&nbsp;Mr.
Pucci&nbsp;worked at Bayer AG, where he served in a number of leadership capacities, including President of the Oncology &amp;
Global Specialty Medicines Business Units and was a member of the Bayer Pharmaceuticals Global Management Committee. Before Bayer
AG,&nbsp;Mr. Pucci&nbsp;held positions of increasing responsibility with Eli Lilly and Company, culminating with his appointment
as Managing Director,&nbsp;Eli Lilly Sweden AB.&nbsp;Mr. Pucci&nbsp;earned an MS in economics and accounting from Universit&agrave;
degli Studi di Napoli Federico II and an MBA in marketing and finance from the&nbsp;University of Chicago.&nbsp;Mr. Pucci&nbsp;has
previously served on the boards of directors of several successful biotech companies, including Algeta ASA, until it was acquired
by Bayer AG and&nbsp;Dyax Inc., until it was acquired by Shire Plc.&nbsp;Mr. Pucci&nbsp;currently serves as a board member of&nbsp;West
Pharmaceuticals Services, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with
his service on the Board, Mr.&nbsp;Pucci&nbsp;will receive an annual cash retainer of $35,000, prorated based on the date of his
appointment to the Board. In addition, Mr. Pucci received a grant of a nonqualified stock option to acquire 33,000 shares of the
Company&#8217;s common stock at an exercise price equal to the closing price of the Company&#8217;s common stock on the Effective
Date, as reported on the Nasdaq Global Select Market. The option will vest and become exercisable as to 25% of the shares on the
first anniversary of the Effective Date, and the balance of the shares will vest in a series of 24 monthly installments thereafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, Mr.&nbsp;Pucci&nbsp;and
the Company entered into a customary indemnification agreement, a form of which has been previously filed with the SEC, and a board
appointment letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There have been no
transactions with the Company and there are currently no proposed transactions with the Company that would be required to be disclosed
under Item 404(a)&nbsp;of Regulation S-K. No arrangement or understanding exists between Mr.&nbsp;Pucci&nbsp;and any other person
pursuant to which Mr.&nbsp;Pucci&nbsp;was selected as a director of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Separation Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">I</FONT>n
connection with Stephen Gorgol&#8217;s transition from his position as the Company&#8217;s Chief Accounting Officer, on April 3,
2020 the Company and Mr. Gorgol entered into a separation agreement (the &#8220;<U>Separation Agreement</U>&#8221;), pursuant to
which, among other things, Mr. Gorgol agreed to continue providing services to the Company in accordance with a Consulting Agreement
(the &#8220;<U>Consulting Agreement</U>&#8221;). The Separation Agreement also provides that Mr. Gorgol is eligible to receive
full payment of COBRA premiums until the earlier of (i) December 31, 2020 and (ii) the date on which Mr. Gorgol becomes eligible
to participate in another employer&#8217;s group health plan and includes customary confidentiality, cooperation and non-disparagement
covenants as well as a general release in favor of the Company and its affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the
Consulting Agreement, Mr. Gorgol will provide services to the Company as a consultant on an as-needed basis on matters
related to transition support, completion of year-end accounting requirements, completion of special projects and such other
services to be determined and reasonably requested from time to time by the Company for an initial term ending on December
31, 2020 (the &#8220;<U>Initial Term</U>&#8221;). The term of the Consulting Agreement may be renewed for successive
one-month periods after the expiration of the Initial Term (each such period, a &#8220;<U>Renewal Period</U>&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.35pt">The Consulting Agreement
provides that Mr. Gorgol will receive a consulting fee in an amount equal to $27,100 per month during the Initial Term. In addition,
Mr. Gorgol is eligible to receive two discretionary milestone payments in an aggregate amount equal to $90,000 in connection with
completion of the Company&#8217;s 2019 audited financials and Mr. Gorgol&#8217;s completion of the services in accordance with
the Consulting Agreement. During any Renewal Period, Mr. Gorgol will receive an hourly consulting fee in an amount of $175 per
hour. Further, the Consulting Agreement provides that Mr. Gorgol&#8217;s options to acquire the Company&#8217;s common stock will
continue to vest until the earlier of: (i) the termination of the Consulting Agreement and (ii) December 31, 2020. If Mr. Gorgol
continues to provide consulting services under the Consulting Agreement through December 31, 2020, all vested and exercisable options
will remain exercisable until the earlier of: (a) the end of the applicable option term and (ii) one year following the end of
the term of the Consulting Agreement. Any options that are unvested as of December 31, 2020 will automatically be forfeited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.35pt">Jean Franchi, the
Company&rsquo;s Chief Financial Officer, will replace Mr. Gorgol as the Company&rsquo;s Principal Accounting Officer on the effective
date of Mr. Gorgol&rsquo;s Separation Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.35pt">Information regarding Ms. Franchi required by Items&nbsp;401
and Item&nbsp;404&nbsp;of&nbsp;Regulation S-K&nbsp;is hereby incorporated by reference to the Company&rsquo;s current report on&nbsp;Form
8-K&nbsp;filed with the SEC on December 9, 2019.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.35pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 10%; text-underline-color: #000000"><FONT STYLE="font-size: 10pt"><B>Item 7.01</B></FONT></TD>
    <TD STYLE="width: 90%; text-underline-color: #000000"><FONT STYLE="font-size: 10pt"><B>Regulation FD Disclosure.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 2, 2020, the
Company issued a press release announcing Mr.&nbsp;Pucci&#8217;s appointment to the Board and the appointment of Dieter Weinand,
a current member of the Board, as Chairman of the Board. The full text of this press release is furnished as Exhibit&nbsp;99.1
to this Current Report on Form&nbsp;8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information contained
in this Item 7.01 and in the accompanying Exhibit 99.1 shall not be incorporated by reference into any filing of the Company, whether
made before or after the date hereof, regardless of any general incorporation language in such filing, unless expressly incorporated
by specific reference to such filing. The information in this Item 7.01 and the accompanying Exhibit 99.1 shall not be deemed to
be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the
liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 10%; text-underline-color: #000000"><FONT STYLE="font-size: 10pt"><B>Item 9.01</B></FONT></TD>
    <TD STYLE="width: 90%; text-underline-color: #000000"><FONT STYLE="font-size: 10pt"><B>Financial Statements and Exhibits.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; width: 10%; text-underline-color: #000000"><FONT STYLE="font-size: 10pt"><B>Exhibit&nbsp;No.</B></FONT></TD>
    <TD STYLE="width: 2%; text-underline-color: #000000; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 88%; text-underline-color: #000000"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-underline-color: #000000">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-underline-color: #000000">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-underline-color: #000000">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-underline-color: #000000"><A HREF="tm2015110d1_ex99-1.htm"><FONT STYLE="font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-underline-color: #000000">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-underline-color: #000000"><A HREF="tm2015110d1_ex99-1.htm"><FONT STYLE="font-size: 10pt">Press release dated April 2,
    2020.</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 13.5pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: #000000">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-underline-color: #000000"><FONT STYLE="font-size: 10pt"><B>REPLIMUNE GROUP, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%; text-underline-color: #000000">&nbsp;</TD>
    <TD STYLE="width: 3%; text-underline-color: #000000">&nbsp;</TD>
    <TD STYLE="width: 46%; text-underline-color: #000000">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: #000000"><FONT STYLE="font-size: 10pt">Date: April 6, 2020</FONT></TD>
    <TD STYLE="text-underline-color: #000000"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-underline-color: #000000"><FONT STYLE="font-size: 10pt">/s/ Jean Franchi</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: #000000">&nbsp;</TD>
    <TD STYLE="text-underline-color: #000000">&nbsp;</TD>
    <TD STYLE="text-underline-color: #000000"><FONT STYLE="font-size: 10pt">Jean Franchi </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: #000000">&nbsp;</TD>
    <TD STYLE="text-underline-color: #000000">&nbsp;</TD>
    <TD STYLE="text-underline-color: #000000"><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2015110d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Replimune Appoints Dieter Weinand as
Chairman and Paolo Pucci to the Board of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Woburn, MA, April 2, 2020</B> &#8211; Replimune Group Inc.
(Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic&#8482; platform,
today announced the appointment of Dieter Weinand as Chairman of the Board of Directors and the new appointment of Paolo Pucci
to the Board of Directors, effective immediately. Mr. Weinand succeeds Philip Astley-Sparke who in January transitioned from part
time Executive Chairman to full time Chief Executive Officer.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8220;We are pleased to announce these changes to our Board.
Dieter has served on the Replimune Board since June 2018 and I am delighted he has agreed to step up to the Chairman role following
my appointment as Chief Executive Officer,&#8221; said Philip Astley-Sparke, Chief Executive Officer of Replimune. &#8220;Both
Dieter and Paolo bring to Replimune vast international experience within commercial, operational, and strategic functions in the
pharmaceutical industry with strong and relevant profiles as we progress our products towards the market. Paolo has extensive experience
in the field of oncology while at Bayer and, more recently, at the helm of ArQule Inc., a Nasdaq-listed oncology and rare diseases
company that was sold to Merck for approximately $2.7 billion in January 2020.&#8221;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mr. Dieter Weinand was formally the Executive Vice President
of Primary Care and a member of the Executive Committee at Sanofi since November 1, 2018. Before moving to Sanofi, Mr. Weinand
was the President of The Pharmaceuticals Division and member of the Management Board at Bayer AG. Prior to his work at Sanofi and
Bayer, Mr. Weinand has held various positions in commercial, operational and strategic areas of the pharmaceutical industry. These
included responsibilities spanning various therapeutic areas and geographies for companies such as Pfizer, Bristol Myers Squibb
and Otsuka. Mr. Weinand earned an MS in Pharmacology and Toxicology from Long Island University, New York, and a BA in biology
from Concordia College, New York. Mr. Weinand is a board member of the Pharmaceutical Research and Manufacturers of America (PhRMA),
a board member of the European Federation of Pharmaceutical Industries &amp; Associations (EFPIA), a member of the Board of Directors
of HealthPrize Technologies.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mr. Paolo Pucci most recently served as the Chief Executive
Officer of ArQule, Inc., a biopharmaceutical oncology company engaged in the research and development of targeted therapeutics
that was acquired by Merck in January 2020. Prior to joining ArQule in 2008, Mr. Pucci worked at Bayer AG, where he served in a
number of leadership capacities including President of the Oncology &amp; Global Specialty Medicines Business Units and was a member
of the Bayer Pharmaceuticals Global Management Committee. Before Bayer AG, Mr. Pucci held positions of increasing responsibility
with Eli Lilly and Company, culminating with his appointment as Managing Director, Eli Lilly Sweden AB. Mr. Pucci earned an MS
in economics and accounting from Universit&agrave; degli Studi di Napoli Federico II and an MBA in marketing and finance from the
University of Chicago. Mr. Pucci has previously served on the Board of several successful biotech companies including Algeta ASA,
until it was acquired by Bayer AG and Dyax Inc., until it was acquired by Shire Plc. Mr. Pucci currently serves as a board member
of West Pharmaceuticals Services, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Replimune </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Replimune Group Inc., headquartered in
Woburn, MA, was founded in 2015 to develop the next generation of &#8220;oncolytic immune-gene therapies&#8221; for the treatment
of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective
virus replication and the potency of the immune response to the tumor antigens released. The Company&#8217;s Immulytic<FONT STYLE="color: #444444; background-color: #FEFEFE"><I><SUP>&#8482;
</SUP></I></FONT>platform is designed to maximize systemic immune activation, in particular to tumor neoantigens, through robust
viral-mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune-activating proteins to the tumor
and draining lymph nodes. The approach is expected to be highly synergistic with immune checkpoint blockade and other approaches
to cancer treatment. Replimune intends to progress these therapies rapidly through clinical development in combination with other
immuno-oncology products with complementary mechanisms of action.&nbsp;For more information, please visit <U>www.replimune.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange
Act of 1934, as amended, including statements regarding our expectations about our cash runway, our goals to develop and commercialize
our product candidates, and other statements identified by words such as &#8220;could,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221;
 &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;potential,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would,&#8221;
or similar expressions and the negatives of those terms. Forward-looking statements are not promises or guarantees of future performance,
and are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results
to differ materially from those contemplated in such forward-looking statements. These factors include risks related to our limited
operating history, our ability to generate positive clinical trial results for our product candidates, the costs of operating our
in-house manufacturing facility, the timing and scope of regulatory approvals, changes in laws and regulations to which we are
subject, competitive pressures, our ability to identify additional product candidates, political and global macro factors including
the impact of the coronavirus as a global pandemic and related public health issues, and other risks as may be detailed from time
to time in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and other reports we file with the Securities and
Exchange Commission. Our actual results could differ materially from the results described in or implied by such forward-looking
statements. Forward-looking statements speak only as of the date hereof, and, except as required by law, we undertake no obligation
to update or revise these forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Replimune Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investor Inquiries </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chris Brinzey</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Westwicke, an ICR Company</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">339.970.2843</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">chris.brinzey@westwicke.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Media Inquiries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Arleen Goldenberg</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Verge Scientific Communications</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">917.548.1582</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">agoldenberg@vergescientific.com</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection Last; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
